This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary Biological Therapeutics Development
BioVenic is dedicated to advancing animal healthcare through innovative veterinary biological therapeutics. With a robust portfolio spanning therapeutic antibodies, therapeutic proteins and peptides, and sophisticated cell-based therapies, BioVenic empowers veterinary researchers, pharmaceutical companies, and animal healthcare providers with cutting-edge biological solutions. Our mission is to leverage our extensive biotechnological expertise and state-of-the-art platforms to deliver scientifically robust, customized therapeutic interventions for companion animals, addressing previously unmet medical needs effectively.
Our Veterinary Biological Therapeutics Development Service
Veterinary Therapeutic Antibody Development
BioVenic offers advanced veterinary antibody development services tailored to companion animals. Our innovative platforms, including hybridoma technology, single B cell sorting, and phage display, facilitate the rapid identification and preparation of species-specific therapeutic antibodies. We employ cutting-edge antibody engineering technologies such as antibody caninization and felinization, ensuring compatibility and effectiveness. Rigorous preclinical testing, including extensive in vitro and in vivo analyses, guarantees safety and efficacy for conditions such as cancer, autoimmune diseases, inflammation, and allergies.
Veterinary Therapeutic Protein and Peptide Development
Our veterinary protein and peptide therapeutics platform is designed for comprehensive discovery, characterization, optimization, and formulation of biologically active molecules. Leveraging display technologies (phage, ribosomal, mRNA), venomics, and rational design, BioVenic rapidly identifies and optimizes veterinary therapeutic proteins and peptides. Our advanced delivery systems, including engineered nanoparticles and liposomes, significantly enhance therapeutic efficacy and bioavailability. These solutions effectively address a wide spectrum of veterinary health issues, from metabolic and hormonal imbalances to infectious diseases.
Veterinary Cell-Based Therapy Development
BioVenic's veterinary cell therapy platform encompasses autologous, allogeneic, and xenogeneic cell sources, tailored for animal-specific therapeutic needs. Specializing in cell types such as mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and immune cells, we integrate advanced genetic editing (CRISPR/Cas9), synthetic biology, and biomaterial techniques to enhance therapeutic cell functionality. Comprehensive preclinical assessments ensure that our veterinary cell therapies deliver robust, safe, and durable treatment outcomes, addressing degenerative diseases, genetic disorders, and cancers resistant to conventional therapies.
Service Workflow for Veterinary Biological Therapeutics Development
BioVenic follows a clear, efficient, and integrated workflow for veterinary biological therapeutic development, ensuring seamless progression from concept to final product:
Fig.1 Veterinary biological therapeutics development service workflow. (BioVenic Original)
Technical Support for Veterinary Biological Therapeutics Development
BioVenic ensures that our veterinary biological therapeutic solutions are robust, precise, and highly effective by leveraging cutting-edge technologies and advanced scientific methodologies. Our specialized technical platforms are at the core of our services, providing researchers and veterinarians with unparalleled capabilities to discover, develop, optimize, and validate innovative veterinary therapeutics.
| Area | Key Technologies |
|---|---|
| Antibody Development | Hybridoma Technology |
| Single B Cell Sorting | |
| Phage Display | |
| CRISPR & siRNA Screening | |
| Antibody Engineering (Caninization/Felinization, Fc Engineering) | |
| Next-Generation Sequencing (NGS) | |
| Protein & Peptide Therapeutics Development | Display Technologies (Phage, Ribosomal, mRNA, Yeast) |
| Venomics and Rational Design | |
| Surface Plasmon Resonance (SPR) | |
| Liposome and Nanoparticle Delivery Systems | |
| Protein Expression Systems (Bacterial, Yeast, Mammalian) | |
| Structural and Functional Analysis | |
| Cell-based Therapy Development | Stem Cell Technologies (MSCs, iPSCs) |
| Immune Cell Engineering | |
| CRISPR-Cas9 Genome Editing | |
| Synthetic Biology | |
| Biomaterial Integration | |
| Cellular Phenotype and Function Analysis (qPCR, Flow Cytometry) |
Why Choose Our Veterinary Biological Therapeutics Development Service
Comprehensive Capabilities
From therapeutic antibodies to proteins, peptides, and advanced cell-based therapies, BioVenic offers a complete range of services under one umbrella, eliminating the complexities of coordinating multiple vendors and ensuring consistent, high-quality results.
Scientific Excellence
BioVenic maintains a robust commitment to scientific rigor and innovation, employing cutting-edge technologies and industry-leading methodologies that ensure superior therapeutic effectiveness and safety.
Tailored Client Support
Understanding that every veterinary project has unique goals and challenges, BioVenic offers personalized services and close collaboration, ensuring project alignment with the client's vision and veterinary therapeutic objectives.
Cost Efficiency and High-Quality Delivery
Our streamlined processes and integrated platforms enable us to deliver high-quality therapeutic solutions cost-effectively, providing outstanding value without compromising on scientific rigor or product quality.
FAQs
What animal models are available for testing veterinary biologicals?
We offer access to both rodent models and target species (e.g., canine, feline) for evaluating safety, efficacy, immunogenicity, and pharmacokinetics of veterinary antibodies, proteins, peptides, and cell-based therapeutics.
How does BioVenic ensure species-specific immune compatibility in biologics?
We incorporate bioinformatics, structural modeling, and species-matched sequence libraries to engineer biologics—especially antibodies—that reduce immunogenicity and enhance efficacy in target animals such as dogs or cats.
Can BioVenic help in developing diagnostic companion tools for therapeutic monitoring?
Yes. We support the co-development of ELISA kits, biomarker assays, and companion diagnostics that can be used to monitor treatment response or immune reactions during veterinary therapeutic studies.
References
- Wang, Jianzhong, et al. "Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine." Animals 15.4 (2025): 472. https://doi.org/10.3390/ani15040472
- Williams, Zoë J., et al. "Evaluation of stem-cell therapies in companion animal disease models: a concise review (2015-2023)." Stem Cells 42.8 (2024): 677-705. https://doi.org/10.1093/stmcls/sxae034